Graybug Vision, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Frederic Guerard
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 203 Redwood Shores Parkway Redwood City CA United States of America 94065
- IPO Date
- Sep 4, 2020
- CIK
- 0001534133
- Website
- graybug.vision
- Similar Companies
- Business
- Graybug Vision, Inc. (NASDAQ: GRAY) is a clinical-stage biopharmaceutical company that develops transformative medicines for the treatment of diseases of the retina and optic nerve, utilizing proprietary microparticle-based drug delivery technologies to enable sustained-release intravitreal implants that reduce dosing frequency; core pipeline products include GB-102, a pan-VEGF inhibitor sunitinib formulation in Phase 2 for wet age-related macular degeneration and diabetic macular edema; GB-401, a prodrug of timolol implant for primary open-angle glaucoma; GB-103 for additional retinal indications; GB-501 for corneal disease; GB-601, acquired from Mireca Medicines GmbH, as mutation-agnostic cGMP analogs for inherited retinal diseases; and GB-701 partnered with Insilico Medicine for geographic atrophy via AI-discovered factor B inhibitors. Founded in 2011 as a spin-out from the Johns Hopkins University School of Medicine's Wilmer Eye Institute and headquartered in Redwood City, California, with a research center in Baltimore, Maryland, the company targets patients with vision-threatening ocular conditions including wet AMD, diabetic retinopathy, glaucoma, corneal diseases, and inherited retinal disorders across North America and global markets through clinical partnerships with leading ophthalmology institutions such as Stanford University, Johns Hopkins, and UCSF. In recent major developments within the last two years, Graybug Vision completed a merger with CalciMedica Inc. in March 2023, under which CalciMedica became the surviving entity trading as CALC and shifted focus to inflammatory disease therapies like Auxora while retaining Graybug's ocular assets; announced pipeline expansions in 2022 with new assets for corneal, inherited retinal, and geographic atrophy indications; filed for an up-to-$86 million IPO on NASDAQ in July 2025 to fund advancement of its ophthalmology portfolio; and continues Phase 2 trials for GB-102 with projected revenues reaching $50 million by year-end 2025 from sustained-release therapy commercialization amid a $14.5 billion ocular therapeutics market.
Grayscale Investments Launches the Lowest Gross Fee Hyperliquid ETP in the U.S. with Grayscale® Hyperliquid Staking ETF (Ticker: HYPG)
Graycliff Receives Drill Results up to 3030 g/t Gold over 1.0 metre at Shakespeare Gold Project, Ontario
GRAY ANNOUNCES QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE
Grayscale Investments® Announces Rebalancing of Multi-Asset Funds for First Quarter 2026
Graycliff Exploration Announces New CFO and Independent Director
Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)
Graycliff Exploration Closes Oversubscribed Private Placement
GRAY SETS DATE FOR FIRST QUARTER EARNINGS RELEASE AND EARNINGS CONFERENCE CALL
BlackRock's ETHB: A Potential Contender To Grayscale's ETH
Graybug Vision (NASDAQ:GRAY) Trading Up 10% – Still a Buy?
Graycliff Exploration Announces Private Placement
Graycliff Exploration to Acquire Geologic Data Related to Its Shakespeare Gold Project
GRAY ANNOUNCES QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE
PORTLAND FIRE AND PORTLAND THORNS ANNOUNCE LANDMARK BROADCAST PARTNERSHIP WITH GRAY MEDIA'S FOX 12 PLUS (KPDX)
U.S. IPO Weekly Recap: IPO Market Stays Fairly Quiet During The Short Holiday Week
Graybug Vision (NASDAQ:GRAY) versus NexImmune (OTCMKTS:NEXI) Head-To-Head Review
Graycliff Exploration Provides Update on Private Placement
GRAY SETS DATE FOR FOURTH QUARTER EARNINGS RELEASE AND EARNINGS CONFERENCE CALL
Ampio Pharmaceuticals (NYSE:AMPE) and Graybug Vision (NASDAQ:GRAY) Financial Contrast
Grayscale Ethereum ETF becomes first in the U.S. to distribute staking rewards: CNBC Crypto World